Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Int J Cardiol ; 112(2): e50-2, 2006 Sep 20.
Article in English | MEDLINE | ID: mdl-16860419

ABSTRACT

Fistula formation between a coronary artery bypass graft and a cardiac cavity is an uncommon finding. We describe a case of transcatheter occlusion of a coronary artery bypass graft to right ventricle fistula in a patient presenting with a subacute inferior myocardial infarction.


Subject(s)
Balloon Occlusion , Coronary Artery Bypass/adverse effects , Fistula/therapy , Heart Diseases/therapy , Heart Ventricles , Aged , Coronary Aneurysm/etiology , Coronary Aneurysm/therapy , Coronary Angiography , Female , Fistula/etiology , Heart Diseases/etiology , Humans , Myocardial Infarction/etiology , Saphenous Vein/transplantation
3.
J Cardiothorac Vasc Anesth ; 8(4): 431-6, 1994 Aug.
Article in English | MEDLINE | ID: mdl-7948800

ABSTRACT

Sotalol is a beta-adrenergic blocking drug with the additional property of lengthening the cardiac action potential. These electrophysiologic properties render the drug attractive for use in the prevention of postoperative supraventricular arrhythmias (SVA), and previous studies have suggested that it was indeed effective. The hemodynamic response to sotalol and its safety early after coronary artery bypass graft (CABG) surgery were therefore studied. Forty-two patients undergoing CABG were randomly assigned either to receive sotalol to prevent postoperative SVA (25 patients) or to serve as controls (17 patients). Sotalol was started 6 hours after surgery if patients had a cardiac index > 2.8 L/min/m2 with a pulmonary capillary wedge pressure < 15 mmHg, and if they had no contraindications to the use of beta-blockers. The drug was given as a loading infusion of 1 mg/kg over 2 hours, followed by a maintenance infusion of 0.15 mg/kg/h for 24 hours. Three hours later, patients received the first oral dose of 80 mg to be repeated every 8 or 12 hours. Adverse effects necessitating discontinuation of the drug (bradycardia < 50 beats/min, systolic blood pressure < 90 mmHg, or cardiac index < 2.2 L/min/m2) occurred in six patients (24%) and were mainly related to the loading infusion. The hemodynamic data for patients who completed the study were characterized by a significant fall of the cardiac index caused by a lower heart rate without significant change of the stroke volume index. The incidence of supraventricular arrhythmias was not significantly different in the two groups (3/19 in the sotalol group, 5/17 in the control group).(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Arrhythmias, Cardiac/prevention & control , Coronary Artery Bypass , Sotalol/therapeutic use , Administration, Oral , Atrial Fibrillation/etiology , Atrial Flutter/etiology , Bradycardia/chemically induced , Cardiac Output/drug effects , Cardiopulmonary Bypass , Coronary Artery Bypass/adverse effects , Female , Heart Rate/drug effects , Hemodynamics/drug effects , Humans , Infusions, Intravenous , Male , Middle Aged , Safety , Sotalol/administration & dosage , Sotalol/adverse effects , Sotalol/blood , Tachycardia, Supraventricular/etiology , Vascular Resistance/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL